Compare STKS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | IMUX |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.6M | 152.6M |
| IPO Year | 2011 | 2013 |
| Metric | STKS | IMUX |
|---|---|---|
| Price | $1.74 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.70 | ★ $4.80 |
| AVG Volume (30 Days) | 46.4K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.66 | $0.51 |
| 52 Week High | $5.19 | $1.51 |
| Indicator | STKS | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 53.23 |
| Support Level | $1.67 | $1.05 |
| Resistance Level | $2.03 | $1.35 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 21.62 | 53.13 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.